At Sanofi and Regeneron, it’s all about the kids—at least with respect to their recent advancements of anti-inflammatory powerhouse Dupixent. On Thursday, the FDA signed off on the IL-4 receptor alpha antagonist to treat children between the ages of 1 and 11 who weigh at least 33 pounds with eosinophilic esophagitis (EoE). Dupixent becomes the first treatment in the U.S. for children in this age group with the disorder.